The FDA today approved Pfizer’s Prevnar 13, indicated for the active immunization of children to prevent invasive disease caused by Streptococcus pneumoniae. Just hours after the approval, the Advisory Committee on Immunization Practices recommended changes to the immunization schedule to incorporate the newly approved vaccine.
…the vaccine is approved for use in children 6 weeks through 5 years and includes the seven serotypes in pneumococcal conjugate vaccine 7-valent — 4, 6B, 9V, 14, 18C, 19F and 23F — plus six additional serotypes — 1, 3, 5, 6A, 7F, and the virulent 19A — a growing health threat that accounts for about 10% of the bacterial diseases….
FDA Approves Prevnar13
Posted in: Pneumococcal/Prevnar
